Health Care · Pharmaceutical Preparations

INSM Insmed Incorporated SEC Filings & Insider Trading Activity 2026

company
CIK 1104506138 filings
Nasdaq 100

INSM at a glance

Insmed Incorporated (INSM, SEC CIK 1104506) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Insmed Incorporated (INSM) reported revenue of $606.4 million (up 66.7% from FY2024) and a net loss of $1.3 billion. Diluted EPS was -$6.42.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Insmed Incorporated (INSM) shares worth $9.4 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Schaeffer Orlov S Nicole on November 19, 2026 of 90,299 shares at $145.06 per share.
  • In the last 90 days, INSM insiders reported 0 open-market purchases ($0) and 4 open-market sales ($17.8M) on Form 4, a net sale of $17.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$606.4M
+66.7% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$17.8M
13F holders
38 funds
$9.4B · +3 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • FDA accelerated approval of ARIKAYCE contingent on successful ENCORE confirmatory trial with 425 patients enrolled as of Q4 2024
  • Exposure to inflation affecting suppliers, service providers, and partners across US, Europe, Japan, and global operations
  • Dependence on Lamira device regulatory approval in each market for ARIKAYCE commercialization limits product sales capability
  • Competitive market risks amid reliance on market acceptance against alternatives amid safety concerns like US boxed warning on ARIKAYCE
  • Outstanding term loan and royalty financing arrangement may limit financial flexibility and increase risk of shareholder dilution

Management Discussion & Analysis

  • Respiratory therapeutic area is the only commercial segment with two approved products: ARIKAYCE and BRINSUPRI
  • No cash flow, buybacks, dividends, or capex details mentioned
  • Forward-looking: portfolio focused on Respiratory, Inflammation & Immunology, Neuro & Rare diseases, with ongoing clinical and pre-clinical programs spanning advanced modalities

Business Overview

  • Core business model: Development and commercialization of specialty pharmaceuticals focusing on respiratory diseases, including key marketed products ARIKAYCE and BRINSUPRI
  • New product emphasis: BRINSUPRI launch in August 2025 generated $172.7M US sales in 2025, contributing to 66.7% overall revenue growth to $606.4M
  • Strategic shift: Accelerated commercial readiness and significant investment in BRINSUPRI’s US launch, plus acquisition of INS1148 for $40M in 2025, expanding pipeline
  • Notable quantitative metrics: R&D expenses rose 28.9% to $771.1M, SG&A increased 52.1% to $701.2M, driven by headcount growth and commercial activities for BRINSUPRI
  • Unique fact: Completed two large equity offerings in 2024 and 2025, raising net proceeds of $713.2M and $823.3M respectively, bolstering cash reserves to support operations

AI summary of the INSM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $524.4M, up $382.1M or 268% YoY, driven by BRINSUPRI
  • BRINSUPRI revenue $400.1M vs $28.1M, while ARIKAYCE revenue rose 9% to $124.4M
  • Cost margin 85.1% vs 79.4% YoY, based on product costs of 14.9% vs 20.6% of revenue
  • Cash and securities $1.15B vs $1.43B at December 31, 2025, with $348.0M operating cash use
  • Outlook: funding expected for at least 12 months, with BRINSUPRI commercialization and TPIP development driving cash needs

Risk Factors

  • No material risk-factor changes identified versus the December 31, 2025 Form 10-K
  • Carried-forward business risk: risks could materially affect financial condition, operations, growth prospects, and common-stock value
  • Carried-forward disclosure risk: actual results may differ materially from forward-looking statements
  • Filing provides no new regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks

AI summary of the INSM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 2026 revenue $524.4M, up 268% year over year, led by BRINSUPRI’s U.S. launch
  • BRINSUPRI revenue $400.1M, up 29% sequentially, supporting raised 2026 guidance to $1.35B-$1.4B

Item EX-99.2: Item EX-99.2

  • Q3 revenue $524.4M, up from $142.3M, driven by BRINSUPRI’s $400.1M launch performance
  • BRINSUPRI full-year 2026 guidance raised to $1.35B-$1.4B from $1.25B-$1.4B

Item 2.02: Results of Operations and Financial Condition

  • Insmed announced third-quarter results for the period ended September 30, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary
Filed Oct 20, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expansion effective October 19, 2026: Paul Hudson, Class II, and Utpal Koppikar, Class I, stand for election in 2027
  • Hudson adds global biopharma CEO experience, including Sanofi and Novartis Pharmaceuticals leadership

Item EX-99.1: Item EX-99.1

  • Paul Hudson, former Sanofi and Novartis Pharmaceuticals CEO, appointed independent director effective immediately
  • Utpal Koppikar, Verily CFO and former Atara Biotherapeutics CFO, appointed independent director effective immediately

Item 7.01: Regulation FD Disclosure

  • Press release announces appointments of Mr. Hudson and Mr. Koppikar
  • Leadership changes may affect strategic execution and investor expectations
Filed Oct 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • October 5, 2026 press release announces Ms. Bonstein’s separation from Insmed
  • Third-quarter 2026 guidance information disclosed, potentially affecting near-term investor expectations

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Sara Bonstein departing October 30, 2026
  • Successor search underway, creating near-term finance leadership transition risk

Item EX-99.1: Item EX-99.1

  • CFO Sara Bonstein departs October 30 after nearly seven years, creating a senior finance leadership transition
  • No accounting, financial-statement, internal-control, or operational disagreement cited, reducing governance concern

AI summaries of INSM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for INSM

Don't miss the next INSM filing

  • Alerts as it files. A push when INSM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut INSM, by share count.
  • Ask anything. An AI agent that reads every INSM filing and answers with sources.

INSM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schaeffer Orlov S NicoleMNov 19, 2026-
Schaeffer Orlov S NicoleMNov 19, 2026-
Schaeffer Orlov S NicoleMNov 19, 2026$26.43
Schaeffer Orlov S NicoleSellNov 19, 2026$145.06
Schaeffer Orlov S NicoleSellNov 19, 2026$147.50
Schaeffer Orlov S NicoleSellNov 19, 2026$146.76
Schaeffer Orlov S NicoleMNov 19, 2026$30.46
Koppikar UtpalAOct 19, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$363.7M$606.4M
Operating Income-$709.6M-$878.3M-$1.2B
Net Income-$749.6M-$913.8M-$1.3B
Op. Margin--241.5%-205.6%
Net Margin--251.2%-210.5%
Balance Sheet
Total Assets$1.3B$2.0B$2.3B
Equity-$285.4M$739.0M
ROE--320.2%-172.8%
Per Share
EPS$-5.34$-5.57$-6.42
Cash Flow
Operating CF--$683.9M-$935.0M
CapEx-$21.9M$32.6M

Source: XBRL data in Insmed Incorporated (INSM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate INSM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
INSM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$9.37B
Q2 202635$10.90B
Q1 202637$18.45B
Q4 202534$18.64B
Q3 202534$18.22B
Q2 202532$9.06B
Q1 202529$4.05B
Q4 202425$3.07B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 264 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

INSM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
10-QOct 29, 2026Analysis
8-KOct 29, 2026Analysis-
8-KOct 20, 2026Analysis-
4Oct 20, 2026--
4Oct 20, 2026--
8-KOct 5, 2026Analysis-
4Sep 11, 2026--
4Aug 19, 2026--
4Aug 12, 2026--
4Aug 7, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 24, 2026--
8-KJul 16, 2026Analysis-
4Jul 10, 2026--
4Jul 8, 2026--
4Jun 26, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 10, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-

Related Health Care companies

All Health Care →

INSM SEC filings: frequently asked questions

Are INSM insiders buying or selling?

In the last 90 days, Insmed Incorporated (INSM) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $17.8 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold INSM stock?

As of September 30, 2026, the largest Insmed Incorporated (INSM) holders among the 13F filers tracked by SignalX were BlackRock ($1.8 billion), Vanguard Portfolio Management LLC ($1.2 billion), Vanguard Capital Management LLC ($1.1 billion), JPMorgan Chase & Co ($953.2 million), Ameriprise Financial ($713.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was INSM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Insmed Incorporated (INSM) reported revenue of $606.4 million (up 66.7% from FY2024) and a net loss of $1.3 billion. Diluted EPS was -$6.42. The figures come from the XBRL data in the 10-K.

What are the main risks in INSM's latest 10-K?

In the 10-K filed February 19, 2026, Insmed Incorporated (INSM) flagged: FDA accelerated approval of ARIKAYCE contingent on successful ENCORE confirmatory trial with 425 patients enrolled as of Q4 2024. Exposure to inflation affecting suppliers, service providers, and partners across US, Europe, Japan, and global operations. (AI summary of the Risk Factors section.)

What did INSM report in its latest 8-K?

Insmed Incorporated (INSM) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 revenue $524.4M, up 268% year over year, led by BRINSUPRI’s U.S. launch.

What are the latest INSM SEC filings?

Insmed Incorporated (INSM) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 20, 2026.

What is INSM's SEC CIK number?

Insmed Incorporated (INSM)'s SEC Central Index Key (CIK) is 1104506. EDGAR lists every INSM filing under that number.

Ask anything about INSM

The research agent reads INSM's filings, financials, insider trades and 13F holders, then answers with sources.